Metformin vs Montelukast: side-by-side comparison
Metformin (Biguanide) and Montelukast (Leukotriene receptor antagonist) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Metformin | Montelukast |
|---|---|---|
| Therapeutic class | Biguanide | Leukotriene receptor antagonist |
| CAS | 657-24-9 | 158966-92-8 |
| ATC | A10BA02 | R03DC03 |
| Molecular weight | 129.16 g/mol | 586.18 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Metformin and Montelukast share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Metformin acts by a different mechanism than Montelukast, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Metformin: Metformin's principal effect is to suppress hepatic glucose production by inhibiting mitochondrial complex I, which raises the cellular AMP/ATP ratio and activates AMP-activated protein kinase. Montelukast: Montelukast selectively blocks the CysLT1 receptor, which mediates the action of leukotrienes C4, D4 and E4 — proinflammatory mediators released by mast cells and eosinophils in the airway.
Indications compared
Metformin: Metformin is indicated as first-line oral therapy in adults and selected paediatric populations with type 2 diabetes mellitus, alone or in combination with other antidiabetic agents, including insulin. Montelukast: Montelukast is approved in adults and children for the maintenance treatment of asthma, including exercise-induced bronchospasm, and for the treatment of seasonal and perennial allergic rhinitis when conventional therapy…
Safety profile
Metformin: The most common adverse effects are gastrointestinal: nausea, diarrhoea, abdominal discomfort and metallic taste, often improved by gradual titration, food intake or use of the extended-release formulation. Montelukast: Common adverse effects include headache, gastrointestinal symptoms and upper respiratory tract infection.
Frequently asked questions
Is Metformin better than Montelukast? ▾
Metformin and Montelukast are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Metformin and Montelukast be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Metformin
Products with Montelukast
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.